Semaglutide (Wegovy)

Peptide

Also known as NN9536

Approvedregulatory verdict

Evidence outlook

Approved: Obesity, Atherosclerotic Cardiovascular Disease, MASH / NASH [accelerated] (label: adults; noncirrhotic, moderate to advanced fibrosis)

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Heart Failure with Preserved Ejection Fraction · Phase 3 · investigational in the US

Also approved (3)
JP
  • Wegovy: obesity disease (restricted to BMI >=27 with two or more obesity-related disorders, or BMI >=35)
Product first approved 2023pj.jiho.jp
EU
  • Wegovy: weight management (weight loss and maintenance) in adults with BMI >=30, or >=27 with a weight-related comorbidity
Product first approved 2022EMA
CA
  • WEGOVY® (semaglutide injection) is indicated: • as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: o Adult patients with an initial body mass index (BMI) of ▪ 30 kg/m2 or greater (obesity), or ▪ 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea. o Pediatric patients aged 12 to less than 18 years: ▪ with an initial BMI at the 95th percentile or greater for age and sex (obesity; see Table 1), and ▪ a body...
Product first approved 2021Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
Heart Failure with Preserved Ejection Fraction
NCT04916470 · Novo Nordisk A/S
2021-06-15 – 2023-10-11 · Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
What this study did
MASH / NASH
Obesity
NCT06934655 · Children's Hospital Los Angeles
2026-09-01 – 2033-11-01 · Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
What this study did
NCT07253285 · Novo Nordisk A/S
2026-01-08 – 2033-09-20 · Overweight, Obesity
What this study did
NCT07949474 · University of Minnesota
2027-05-01 – 2033-04-30 · Alcohol Use Disorder (AUD), Obesity
What this study did
NCT07021937 · University of Colorado, Denver
2026-06-15 – 2031-04-30 · Obesity/Therapy
What this study did
NCT07294950 · Mount Sinai Hospital, Canada
2026-02-01 – 2029-05 · Obesity (Disorder), Weight Change, Blood Pressure Monitoring, Appetite Regulation
What this study did
NCT06909006 · Nordsjaellands Hospital
2025-10 – 2028-06 · Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance, Semaglutide, Lipidomics, Metabolomics, Weight Loss, Glycemic Control for Diabetes Mellitus
What this study did
NCT06499857 · University of Chicago
2025-04-14 – 2028-06 · Overweight or Obesity, Atrial Fibrillation
What this study did
NCT06937060 · The University of Hong Kong
2025-03-20 – 2027-01-31 · Psoriasis (PsO), Obesity and Overweight
What this study did
NCT05726227 · Novo Nordisk A/S
2023-07-07 – 2026-12-07 · Obesity
What this study did
NCT06633783 · Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
2024-10-30 – 2026-10-30 · Obesity
What this study did
NCT06616961 · Popular Medical College Hospital
2024-11-01 – 2026-10 · Obesity, Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06041217 · Novo Nordisk A/S
2023-09-15 – 2025-05-07 · Overweight, Obesity
What this study did
NCT05073835 · University College, London
2022-11-01 – 2025-04-09 · Obesity, Diabetes, Metabolic Syndrome
What this study did
NCT05813925 · Novo Nordisk A/S
2023-04-03 – 2025-03-07 · Obesity or Overweight
What this study did
NCT05996848 · Novo Nordisk A/S
2023-08-15 – 2025-02-22 · Obesity or Overweight
What this study did
NCT05646706 · Novo Nordisk A/S
2023-01-04 – 2024-11-26 · Obesity
What this study did
NCT04885634 · Axel Brandes
2022-10 – 2024-11 · Atrial Fibrillation, Overweight and Obesity
What this study did
NCT05087342 · Loma Linda University
2022-12-13 – 2024-05-29 · Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
What this study did
NCT04889183 · University Medical Center Groningen
2022-03-14 – 2024-05-28 · Obesity, Albuminuria
What this study did
NCT04998136 · Novo Nordisk A/S
2022-08-15 – 2023-11-20 · Obesity
What this study did
NCT05064735 · Novo Nordisk A/S
2021-10-01 – 2023-09-08 · Obesity
What this study did
NCT05040971 · Novo Nordisk A/S
2021-09-06 – 2023-07-14 · Obesity
What this study did
NCT04788511 · Novo Nordisk A/S
2021-03-16 – 2023-04-18 · Obesity
What this study did
NCT04251156 · Novo Nordisk A/S
2020-12-08 – 2022-08-23 · Overweight, Obesity, Diabetes Mellitus, Type 2
What this study did
NCT04102189 · Novo Nordisk A/S
2019-10-07 – 2022-03-28 · Overweight, Obesity
What this study did
NCT04074161 · Novo Nordisk A/S
2019-09-11 – 2021-05-11 · Overweight, Obesity
What this study did
NCT03693430 · Novo Nordisk A/S
2018-10-05 – 2021-03-23 · Overweight, Obesity
What this study did
NCT03811574 · Novo Nordisk A/S
2019-01-21 – 2020-11-20 · Overweight, Obesity
What this study did
Other / comorbidity
NCT07090343 · Leiden University Medical Center
2026-04-01 – 2031-04-01 · Aortic Stenosis, Heart Failure
What this study did
Phase 2/3 (4)
Obesity
NCT06423599 · Jens D Hove, MD,PHD
2024-04-30 – 2027-12-30 · Heart Failure With Reduced Ejection Fraction, Obesity, Weight Loss, Chronic Heart Failure
What this study did
NCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2025-01-01 – 2026-02-28 · Polycystic Ovary Syndrome (PCOS) Women, Obesity
What this study did
Other / comorbidity
NCT07797036 · University of Massachusetts, Worcester
2027-09-01 – 2030-12-31 · Gestational Diabetes Mellitus (GDM), Metabolic Syndrome
What this study did
NCT06913023 · University Health Network, Toronto
2026-12-05 – 2029-12-30 · Kidney Transplant Recipient
What this study did
Phase 2 (30)
MASH / NASH
NCT03884075 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2019-07-24 – 2028-10-02 · Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
What this study did
NCT04971785 · Gilead Sciences
2021-08-09 – 2024-12-09 · Nonalcoholic Steatohepatitis
What this study did
NCT03987451 · Novo Nordisk A/S
2019-06-18 – 2021-06-10 · Non-alcoholic Steatohepatitis
What this study did
NCT03987074 · Gilead Sciences
2019-07-29 – 2020-07-13 · Nonalcoholic Steatohepatitis
What this study did
NCT02970942 · Novo Nordisk A/S
2016-11-30 – 2020-03-19 · Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
What this study did
Obesity
NCT05829460 · Washington University School of Medicine
2025-03-12 – 2032-04-30 · Endometrial Hyperplasia
What this study did
NCT07820358 · The Methodist Hospital Research Institute
2027-01-01 – 2031-12-31 · Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
What this study did
NCT07731256 · Washington University School of Medicine
2027-02-01 – 2031-09-01 · Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
What this study did
NCT07946796 · Copenhagen University Hospital at Herlev
2027-01 – 2029-10 · Infertility in Overweight Men
What this study did
NCT07909889 · Aarhus University Hospital
2027-03 – 2029-09 · Breast Cancer (Early Breast Cancer), Obesity
What this study did
NCT06173778 · The University of Texas Health Science Center, Houston
2024-04-23 – 2028-06-25 · Obesity, Overweight, Cigarette Smoking
What this study did
NCT07411378 · Biophytis
2026-07 – 2027-08 · Muscle Wasting, Obesity & Overweight, Obesity
What this study did
NCT07639021 · Novo Nordisk A/S
2026-06-09 – 2027-06-14 · Obesity
What this study did
NCT05173714 · Srinvasan Beddhu
2021-12-01 – 2027-03-31 · Chronic Kidney Diseases, Obesity
What this study did
NCT07101939 · Actimed Therapeutics Ltd
2025-06-23 – 2027-03 · Obesity, Muscle Loss
What this study did
NCT05254314 · Vanderbilt University Medical Center
2022-10-11 – 2026-12-30 · Asthma
What this study did
NCT07505303 · Eccogene
2026-03-23 – 2026-10-15 · Adult Obesity, Weight Management
What this study did
NCT04019197 · Case Western Reserve University
2019-05-16 – 2026-10-09 · HIV/AIDS, Lipohypertrophy, Obesity
What this study did
NCT04873245 · University of Minnesota
2022-03-15 – 2026-06-30 · Obesity, Childhood
What this study did
NCT06771115 · Zomagen Biosciences Ltd.
2025-01-07 – 2025-09-10 · Obesity
What this study did
NCT05895643 · Psychiatric Centre Rigshospitalet
2023-06-13 – 2025-07-31 · Alcohol Abuse, Alcohol Addiction, Alcohol Dependence, Alcohol Use Disorder
What this study did
NCT05616013 · Eli Lilly and Company
2022-11-16 – 2025-06-14 · Obesity, Obese, Overweight or Obesity
What this study did
NCT05302596 · State University of New York at Buffalo
2022-09-01 – 2024-10-30 · Obesity, Aging
What this study did
NCT04969939 · Novo Nordisk A/S
2021-07-15 – 2023-01-30 · Obesity
What this study did
NCT02453711 · Novo Nordisk A/S
2015-10-01 – 2017-04-12 · Metabolism and Nutrition Disorder, Obesity
What this study did
Other / comorbidity
NCT06073184 · GynOncTrials
2026-09-17 – 2032-02 · Endometrial Cancer, Atypical Hyperplasia, Fertility Perservation
What this study did
NCT07282769 · University of Chicago
2026-06 – 2027-02 · Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling Disorder
What this study did
NCT04982575 · Novo Nordisk A/S
2021-08-02 – 2022-07-07 · Diabetes Mellitus, Type 2
What this study did
Phase 1/2 (2)
Obesity
NCT05746039 · University of Pennsylvania
2024-01-29 – 2027-12-28 · Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
What this study did
NCT06541509 · University Medical Centre Ljubljana
2024-07-10 – 2025-09-01 · Heart Failure, Obesity
What this study did
Phase 1 (24)
MASH / NASH
NCT05766709 · Novo Nordisk A/S
2023-03-02 – 2024-02-09 · Non-alcoholic Steatohepatitis
What this study did
Obesity
NCT07527195 · Novo Nordisk A/S
2026-04-10 – 2028-06-09 · Obesity
What this study did
NCT07010432 · Novo Nordisk A/S
2025-06-12 – 2028-05-03 · Obesity
What this study did
NCT06575738 · University of Colorado, Denver
2024-10-11 – 2027-10-01 · Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
What this study did
NCT07845578 · Novo Nordisk A/S
2026-09-25 – 2027-09-11 · Obesity, Overweight
What this study did
NCT07840729 · Shanghai JMT-Bio Inc.
2026-10-20 – 2027-04-30 · Valid MeSH Conditiongs
What this study did
NCT05202353 · Boehringer Ingelheim
2024-11-01 – 2027-02-03 · Obesity
What this study did
NCT07465965 · Shanghai World Leader Pharmaceutical Co., Ltd.
2026-03-02 – 2026-08-30 · Overweight, Obesity
What this study did
NCT07171723 · University Hospital, Gentofte, Copenhagen
2025-09-01 – 2026-08-12 · Obesity &Amp; Overweight
What this study did
NCT06972992 · Ascletis Pharma (China) Co., Limited
2025-04-18 – 2025-09-22 · Chronic Weight Management
What this study did
NCT04779697 · Yale University
2021-02-01 – 2024-11-19 · Obesity
What this study did
NCT05236517 · Novo Nordisk A/S
2022-02-08 – 2022-11-07 · Obesity
What this study did
NCT04238962 · Novo Nordisk A/S
2020-02-03 – 2020-10-20 · Overweight, Obesity
What this study did
NCT04187300 · Novo Nordisk A/S
2019-12-16 – 2020-09-23 · Overweight, Obesity
What this study did
NCT03600480 · Novo Nordisk A/S
2018-07-25 – 2020-06-12 · Obesity, Overweight
What this study did
NCT04228354 · Novo Nordisk A/S
2020-01-29 – 2020-06-01 · Healthy Volunteers, Overweight, Obesity
What this study did
NCT03842202 · Novo Nordisk A/S
2019-02-15 – 2019-11-04 · Overweight, Obesity
What this study did
NCT04012255 · Novo Nordisk A/S
2019-07-15 – 2019-10-22 · Overweight, Obesity
What this study did
NCT03707990 · Novo Nordisk A/S
2018-10-15 – 2019-08-13 · Obesity and Overweight
What this study did
NCT03574584 · Novo Nordisk A/S
2018-06-18 – 2019-07-27 · Metabolism and Nutrition Disorders, Overweight or Obesity
What this study did
Other / comorbidity
NCT07727473 · Banner Health
2026-07 – 2029-05 · Prostate Cancer
What this study did
Phase 4 (40)
Heart Failure with Preserved Ejection Fraction
NCT05371496 · Mayo Clinic
2022-09-06 – 2026-07-17 · Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
What this study did
MASH / NASH
Semaglutide vs Sitagliptinactive not recruiting
NCT05195944 · University Health Network, Toronto
2022-10-26 – 2026-12 · Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
What this study did
Obesity
NCT07769047 · Mayo Clinic
2026-09-01 – 2035-07-30 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
What this study did
NCT06977438 · University of Minnesota
2027-01-01 – 2032-01-31 · Obesity, Childhood
What this study did
NCT06571383 · Novo Nordisk A/S
2024-09-17 – 2031-11-15 · Obesity
What this study did
NCT07872904 · Signe Torekov
2026-10-01 – 2031-01-31 · Obesity, Overweight
What this study did
NCT07592546 · Alain Dagher
2026-10-21 – 2030-06-01 · Class I/II Obesity
What this study did
NCT07900074 · McMaster University
2026-10-31 – 2029-12-31 · Obesity (Disorder)
What this study did
NCT07770152 · Children's Hospital Medical Center, Cincinnati
2026-10-18 – 2029-09-01 · Autism Spectrum Disorder, Obesity
What this study did
NCT07783854 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-09-01 – 2029-06-30 · Obesity & Overweight
What this study did
NCT07859150 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2029-04 · Morbid Obesity
What this study did
NCT07859163 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2029-04 · Morbid Obesity
What this study did
NCT07213466 · Mayo Clinic
2026-01-19 – 2029-02-01 · Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
What this study did
NCT07858331 · Kristin Clemens
2027-01-01 – 2029-01-01 · Obesity, Chronic Kidney Disease, Chronic Renal Disease, CKD
What this study did
NCT07275697 · Emma Svennberg
2026-03-23 – 2028-12-30 · Atrial Fibrillation (AF), Obesity & Overweight
What this study did
NCT07870538 · Universitaire Ziekenhuizen KU Leuven
2026-08-26 – 2028-12 · Obesity & Overweight
What this study did
NCT06814938 · Mayo Clinic
2025-02-21 – 2028-11 · Obesity
What this study did
NCT07859137 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2028-11 · Morbid Obesity
What this study did
NCT07859189 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2028-10 · Morbid Obesity
What this study did
NCT05209165 · San Francisco Veterans Affairs Medical Center
2023-05 – 2028-05 · Atrial Fibrillation, Obesity, Overweight
What this study did
NCT06854614 · The Cleveland Clinic
2025-03-01 – 2028-04-28 · Obesity
What this study did
NCT07859176 · General Committee of Teaching Hospitals and Institutes, Egypt
2026-10 – 2028-04 · Morbid Obesity
What this study did
NCT06852391 · McMaster University
2025-06-18 – 2027-12-31 · Obesity (Disorder)
What this study did
NCT06754163 · St Andrew's Healthcare
2025-01-01 – 2027-12-30 · Obesity and Obesity-related Medical Conditions, Psychiatric Disorders
What this study did
NCT06803888 · Ali Aminian
2025-01-29 – 2027-12-01 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07136714 · Nordsjaellands Hospital
2025-09-11 – 2027-09 · Major Depressive Disorder
What this study did
NCT07242534 · Fundacion Dexeus
2026-01-19 – 2027-05 · Infertility, Obesity
What this study did
NCT07057310 · Mayo Clinic
2025-05-01 – 2027-03-31 · Obesity, Menopause
What this study did
NCT06396416 · Western University, Canada
2024-09-26 – 2026-12 · Obesity, Chronic Kidney Disease
What this study did
NCT06287307 · Zuyderland Medisch Centrum
2024-05 – 2026-09 · Obesity, Obesity, Morbid, Weight Gain
What this study did
NCT05574439 · Signe Torekov
2022-05-30 – 2026-04-01 · Obesity, Adolescent
What this study did
NCT06027567 · Rigmor Højland Jensen
2022-09-02 – 2025-10-28 · Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome, Papilledema, Weight Loss
What this study did
NCT05702905 · Peking University First Hospital
2023-05-09 – 2025-06-30 · PCOS (Polycystic Ovary Syndrome), Semaglutide
What this study did
NCT05548647 · University of Pennsylvania
2022-07-26 – 2025-05-12 · Obesity
What this study did
NCT06468748 · United States Army Research Institute of Environmental Medicine
2024-08-01 – 2025-03-27 · Obesity
What this study did
NCT06863363 · Shanghai Zhongshan Hospital
— · Non-diabetic Obesity
What this study did
NCT05579249 · Novo Nordisk A/S
2023-01-19 – 2024-11-27 · Obesity
What this study did
NCT04263415 · University Medical Centre Ljubljana
2019-11-02 – 2021-10-31 · PCOS, Semaglutide, Taste, Altered, Tongue Tissue Transcriptome, Gastric Emptying, Central Neural Response
What this study did
Other / comorbidity
NCT05616052 · Huashan Hospital
2022-12-01 – 2023-12-01 · Weight Change, Body
What this study did
Early phase / not applicable (21)
MASH / NASH
NCT06764056 · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
2025-01 – 2026-05 · Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
What this study did
Obesity
NCT07621640 · Hallym University
2026-06 – 2031-02 · Obesity, Metabolic Syndrome, Brown Adipose Tissue
What this study did
NCT06885736 · Dasman Diabetes Institute
2025-08-07 – 2029-12-31 · Obesity
What this study did
NCT07589322 · Tri-Service General Hospital (TSGH)
2026-03-31 – 2029-09-30 · Obesity and Metabolic Syndrome
What this study did
NCT07732426 · Seoul National University Hospital
2026-07-15 – 2028-06-30 · Food Addiction Tendency, Obesity, Overweight
What this study did
NCT07633639 · China-Japan Friendship Hospital
2026-05-01 – 2028-05-01 · Obesity
What this study did
NCT07779343 · University of Health Sciences, Algeria
2026-01-22 – 2028-01-23 · Obesity Difficult Airway Airway Management, Obesity Adult Onset, Obesity and Cardiovascular Risk, Obesity Type 2 Diabetes Mellitus
What this study did
NCT06825793 · Beijing Chao Yang Hospital
2025-02-20 – 2027-12-31 · Obesity
What this study did
NCT06497595 · Sheba Medical Center
2025-05-11 – 2027-11-30 · Type 2 Diabetes Mellitus in Obese
What this study did
NCT04174755 · University College Dublin
2022-06-22 – 2027-07 · Obesity, HIV-1-infection
What this study did
NCT07293325 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-06-02 – 2027-06-02 · Adults With Simple Obesity
What this study did
NCT06546384 · Insel Gruppe AG, University Hospital Bern
2026-11-01 – 2027-04-30 · Adiposity, Fatty Liver, Alcohol Use Disorder
What this study did
NCT06989203 · Chinese Academy of Sciences
2025-06-10 – 2026-12-31 · Obesity, Weight Loss, Protein Supplementation
What this study did
NCT07319975 · Istanbul Galata University
2025-12-29 – 2026-12 · Obesity
What this study did
NCT05333003 · Centre for Addiction and Mental Health
2022-05-25 – 2026-08 · Schizophrenia Spectrum Disorders
What this study did
NCT04990024 · American University of Beirut Medical Center
2021-07-01 – 2025-12-15 · Obesity, Weight Loss
What this study did
NCT07280403 · INQUIS Clinical Research
2024-09-12 – 2025-11-30 · Weight Loss
What this study did
NCT06390501 · Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
2024-04-01 – 2025-09-15 · Obesity; Drug
What this study did
NCT06426446 · Assistance Publique - Hôpitaux de Paris
2024-06-01 – 2025-06-01 · Obesity
What this study did
NCT06221696 · S.LAB (SOLOWAYS)
2023-06-12 – 2023-12-01 · Overweight and Obesity
What this study did
NCT06215196 · S.LAB (SOLOWAYS)
2023-04-14 – 2023-08-20 · Overweight and Obesity
What this study did
Used as active comparator (29)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (14)
Obesity
NCT07668414 · Novo Nordisk A/S
2026-09-22 – 2028-10-10 · Overweight, Obesity
What this study did
NCT07919405 · Novo Nordisk A/S
2026-11-11 – 2028-07-13 · Hypertension, Obesity
What this study did
NCT07564414 · Novo Nordisk A/S
2026-05-21 – 2028-04-19 · Obesity, Type 2 Diabetes
What this study did
NCT07845500 · Pfizer
2026-09-30 – 2028-02-16 · Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
What this study did
NCT07622810 · Carnot Laboratories
2026-09 – 2027-12 · Obesity & Overweight
What this study did
NCT07150975 · Gan & Lee Pharmaceuticals.
2025-09-23 – 2027-06-30 · Obesity/Overweight in Adult
What this study did
NCT06884293 · Innovent Biologics (Suzhou) Co. Ltd.
2025-05-09 – 2027-06-30 · Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
What this study did
NCT07285902 · Fujian Shengdi Pharmaceutical Co., Ltd.
2025-12-25 – 2027-03 · Obesity
What this study did
NCT05567796 · Novo Nordisk A/S
2022-11-01 – 2026-10-19 · Obesity
What this study did
NCT06738979 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025-03-20 – 2026-05-26 · Obesity
What this study did
NCT07036172 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-01-03 – 2026-05 · Obesity Control
What this study did
NCT06604624 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2024-09-20 – 2025-09-24 · Weight Management
What this study did
NCT05822830 · Eli Lilly and Company
2023-04-21 – 2024-11-13 · Obesity, Overweight
What this study did
Phase 2 (6)
MASH / NASH
NCT05877547 · Merck Sharp & Dohme LLC
2023-06-23 – 2025-12-29 · Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
What this study did
NCT05016882 · Novo Nordisk A/S
2021-08-31 – 2025-03-14 · Non-alcoholic Steatohepatitis
What this study did
NCT04944992 · Merck Sharp & Dohme LLC
2021-08-04 – 2022-10-19 · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
What this study did
Obesity
NCT07812597 · Beijing QL Biopharmaceutical Co.,Ltd
2026-10-12 – 2028-03-24 · Obesity
What this study did
NCT07073417 · Hangzhou Sciwind Biosciences Co., Ltd.
2025-07-28 – 2027-08-23 · Obesity, Weight Management
What this study did
NCT07836140 · Second Affiliated Hospital of Soochow University
2024-04-22 – 2026-04-30 · Obesity / Overweight
What this study did
Phase 1 (6)
Obesity
NCT07940582 · Novo Nordisk A/S
2026-11-13 – 2028-05-29 · Overweight, Obesity
What this study did
NCT07767175 · Novo Nordisk A/S
2026-08-12 – 2027-09-23 · Overweight, Obesity
What this study did
NCT07673900 · Terrestrial Bio, Inc.
2026-06-15 – 2027-05-18 · Overweight and/or Obesity
What this study did
NCT07430059 · Vivani Medical, Inc
2026-07 – 2027-01 · Obesity & Overweight
What this study did
NCT06745284 · Boehringer Ingelheim
2025-03-26 – 2026-12-01 · Obesity
What this study did
NCT06830343 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2025-02-27 – 2026-10-01 · Overweight or Obesity
What this study did
Phase 4 (2)
Obesity
NCT06410352 · University Medical Center, Kazakhstan
2024-03-01 – 2026-07-31 · Metabolic Syndrome
What this study did
Early phase / not applicable (1)
Obesity
NCT06989177 · Chinese Academy of Sciences
2025-06-10 – 2026-12-31 · Obesity, Homeostasis, Weight Loss, Probiotic Intervention
What this study did
Studied as part of a combination product (10)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (4)
Obesity
NCT06780449 · Novo Nordisk A/S
2025-02-10 – 2028-10-31 · Obesity
What this study did
NCT07011667 · Novo Nordisk A/S
2025-06-03 – 2028-10-17 · Obesity
What this study did
NCT06388187 · Novo Nordisk A/S
2024-06-24 – 2026-04-22 · Obesity
What this study did
NCT06131437 · Novo Nordisk A/S
2023-11-27 – 2026-01-09 · Obesity
What this study did
Phase 1 (6)
Obesity
NCT07184086 · Novo Nordisk A/S
2025-09-26 – 2028-02-09 · Obesity
What this study did
NCT06267092 · Novo Nordisk A/S
2024-02-15 – 2025-12-08 · Overweight, Obesity
What this study did
NCT06207877 · Novo Nordisk A/S
2024-02-23 – 2024-11-22 · Obesity
What this study did
NCT06289504 · Novo Nordisk A/S
2024-02-27 – 2024-11-15 · Obesity
What this study did
NCT04940078 · Novo Nordisk A/S
2021-07-07 – 2022-02-16 · Obesity & Overweight
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (5)
MASH / NASH
NCT07466017 · Cascade Pharmaceuticals, Inc
2026-04-02 – 2027-07-30 · Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
What this study did
Obesity
NCT07446998 · Veru Inc.
2026-03-26 – 2027-12 · Obesity & Overweight, Mobility Disability, HOMA-IR
What this study did
NCT06577090 · Skye Bioscience, Inc.
2024-08-22 – 2027-02-28 · Obesity
What this study did
NCT06282458 · Veru Inc.
2024-04-29 – 2025-08-22 · Muscle Loss, Obesity
What this study did
NCT06500429 · Neurogastrx, Inc.
2024-06-24 – 2024-09-13 · Overweight and Obesity, Healthy
What this study did
Early phase / not applicable (3)
Obesity
NCT07091500 · Washington University School of Medicine
2025-08-11 – 2029-08-01 · Obesity, Skeletal Muscle, Brain Connectivity
What this study did
NCT06836284 · Karolinska Institutet
2026-02-13 – 2027-05-01 · Childhood Obesity, Treatment Adherence
What this study did
NCT07849348 · Peking University People's Hospital
2026-09 – 2027-02 · Obesity; Chronic Kidney Disease; Albuminuria
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Semaglutide (Wegovy): this drugApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Lixisenatide (Adlyxin / Lyxumia)
Approved(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
Albenatide
Phase 3(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Exendin-4 Fc Fusion (JY09)
Phase 3(overall)
Protein / enzyme therapeuticGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HDG1901
Phase 3(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
IcoSema (Kyinsu)
Phase 3(overall)
PeptideInsulin receptor (basal), GLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Noiiglutide
Phase 3(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Pegloxenatide (Fulaimei)
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
Visepegenatide (PB-119)
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication
BW-20829Phase 2RNA / oligonucleotideLipoprotein(a) [Lp(a)] production pathwaynot yet gradedNo reviewed efficacy summary in this indication
CNIC-Ferrer Polypill (Trinomia)Phase 2Small moleculeMulti-mechanism secondary-prevention polypillPartial signalNo reviewed efficacy summary in this indication
DNV001Phase 2RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3Weak signalNo reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
SAL0150
Phase 2(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
TTP273
Phase 2(overall)
Small moleculeGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
XW014
Phase 1(overall)
Small moleculeGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 79 furthest-along competitors are listed; 56 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(73 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Semaglutide (Wegovy) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
December 2026 (6)
Phase 4MASH / NASHActive not recruiting
Est. primary completion 2026-12 · NCT05195944 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2026-12-31 · NCT05173714 · CT.gov ↗
What to watch
Phase 4ObesityEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07057310 · CT.gov ↗
What to watch
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2026-12-31 · NCT06825793 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-12-31 · NCT06989203 · CT.gov ↗
What to watch
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2026-12-31 · NCT06546384 · CT.gov ↗
What to watch
2027 (22)
January 2027 (2)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-01 · NCT04174755 · CT.gov ↗
What to watch
Phase 1ObesityActive not recruiting
Est. primary completion 2027-01-06 · NCT05202353 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling DisorderNot yet recruiting
Est. primary completion 2027-02 · NCT07282769 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-02 · NCT07242534 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-02-28 · NCT07840729 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2ObesityRecruiting
Est. primary completion 2027-03 · NCT07101939 · CT.gov ↗
What to watch
April 2027 (2)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-04-02 · NCT07293325 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-04-28 · NCT06854614 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-06 · NCT07411378 · CT.gov ↗
What to watch
Phase 2ObesityActive not recruiting
Est. primary completion 2027-06-14 · NCT07639021 · CT.gov ↗
What to watch
July 2027 (2)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07-01 · NCT06803888 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07-31 · NCT06754163 · CT.gov ↗
What to watch
September 2027 (4)
Phase 4ObesityRecruiting
Est. primary completion 2027-09 · NCT07136714 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-09-01 · NCT06575738 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-09-11 · NCT07845578 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-09-30 · NCT06497595 · CT.gov ↗
What to watch
December 2027 (6)
Phase 3ObesityRecruiting
Est. primary completion 2027-12 · NCT06499857 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-12 · NCT06814938 · CT.gov ↗
What to watch
Phase 1/2ObesityRecruiting
Est. primary completion 2027-12-28 · NCT05746039 · CT.gov ↗
What to watch
Phase 2/3ObesityRecruiting
Est. primary completion 2027-12-30 · NCT06423599 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-12-30 · NCT07783854 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-12-31 · NCT06852391 · CT.gov ↗
What to watch
2028 (24)
January 2028 (2)
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-01-23 · NCT07779343 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2028-01-31 · NCT06801015 · CT.gov ↗
What to watch
February 2028 (3)
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2028-02 · NCT07621640 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-02-01 · NCT07213466 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-02-29 · NCT07732426 · CT.gov ↗
What to watch
April 2028 (2)
Phase 4ObesityNot yet recruiting
Est. primary completion 2028-04 · NCT07859176 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2028-04-28 · NCT07527195 · CT.gov ↗
What to watch
May 2028 (4)
Phase 1Prostate CancerNot yet recruiting
Est. primary completion 2028-05 · NCT07727473 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-05-01 · NCT07633639 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2028-05-03 · NCT07010432 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2028-05-25 · NCT06173778 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-06 · NCT06909006 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2MASH / NASHRecruiting
Est. primary completion 2028-08-31 · NCT03884075 · CT.gov ↗
What to watch
September 2028 (4)
Phase 3ObesityRecruiting
Est. primary completion 2028-09 · NCT07294950 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-09-01 · NCT07770152 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2028-09-06 · NCT07855133 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-09-30 · NCT07589322 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2028-10 · NCT07859189 · CT.gov ↗
What to watch
November 2028 (2)
Phase 4ObesityNot yet recruiting
Est. primary completion 2028-11 · NCT07859137 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2028-11-15 · NCT06571383 · CT.gov ↗
What to watch
December 2028 (4)
Phase 4ObesityRecruiting
Est. primary completion 2028-12 · NCT07870538 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-12-01 · NCT07592546 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-12-30 · NCT07275697 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2028-12-31 · NCT07820358 · CT.gov ↗
What to watch
2029 (10)
January 2029 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-01-01 · NCT07858331 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Endometrial Cancer, Atypical Hyperplasia, Fertility PerservationRecruiting
Est. primary completion 2029-02 · NCT06073184 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-03 · NCT07909889 · CT.gov ↗
What to watch
April 2029 (3)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-04 · NCT07859150 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-04 · NCT07859163 · CT.gov ↗
What to watch
Phase 3MASH / NASHActive not recruiting
Est. primary completion 2029-04-25 · NCT04822181 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-06 · NCT07946796 · CT.gov ↗
What to watch
Phase 2/3Kidney Transplant RecipientNot yet recruiting
Est. primary completion 2029-06-30 · NCT06913023 · CT.gov ↗
What to watch
August 2029 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-08-30 · NCT06885736 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4ObesityRecruiting
Est. primary completion 2029-12-31 · NCT07900074 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 3ObesityRecruiting
Est. primary completion 2030-03-20 · NCT07253285 · CT.gov ↗
What to watch
May 2030 (1)
Phase 4ObesityRecruiting
Est. primary completion 2030-05-31 · NCT07872904 · CT.gov ↗
What to watch
September 2030 (2)
Phase 2/3Gestational Diabetes Mellitus (GDM), Metabolic SyndromeNot yet recruiting
Est. primary completion 2030-09-01 · NCT07797036 · CT.gov ↗
What to watch
Phase 3Aortic Stenosis, Heart FailureNot yet recruiting
Est. primary completion 2030-09-01 · NCT07090343 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3ObesityRecruiting
Est. primary completion 2030-11-01 · NCT06934655 · CT.gov ↗
What to watch
2031 (5)
January 2031 (2)
Phase 2ObesityNot yet recruiting
Est. primary completion 2031-01-01 · NCT07731256 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2031-01-31 · NCT06977438 · CT.gov ↗
What to watch
March 2031 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2031-03 · NCT07845994 · CT.gov ↗
What to watch
April 2031 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2031-04-30 · NCT07021937 · CT.gov ↗
What to watch
July 2031 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2031-07-30 · NCT07769047 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2032-04-30 · NCT07949474 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(12)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 September 2026Topline resultSTEP Young Phase 3 meets its primary endpoint
Novo Nordisk · Source ↗
July 2026ApprovalWegovy 7.2 mg single-dose pen approved in the EU
EU, EMA · Source ↗
11 June 2026ApprovalWegovy pill (semaglutide tablets) approved in the UK
UK, MHRA · Source ↗
9 April 2026ApprovalEMA approves Wegovy injection 48-hour controlled-temperature delivery
EU, EMA · Source ↗
19 March 2026ApprovalFDA approves the Wegovy 7.2 mg weekly dose (Wegovy HD)
US, FDA · Source ↗
17 February 2026ApprovalEC approves Wegovy 7.2 mg dose for adults with obesity
EU, EMA · Source ↗
22 December 2025ApprovalFDA approves Wegovy pill (oral semaglutide 25 mg) for weight loss
US, FDA · Source ↗
26 November 2025Filing submittedsNDA submitted to FDA for Wegovy 7.2 mg
US, FDA · Source ↗
Q4 2025FDA action dateFDA action date for oral Wegovy set for Q4 2025
US, FDA · Source ↗
15 August 2025ApprovalFDA approves Wegovy for MASH with moderate to advanced liver fibrosis
US, FDA · Source ↗
2 May 2025Filing acceptedFDA accepts NDA for oral Wegovy (semaglutide) 25 mg
US, FDA · Source ↗
19 November 2024Topline resultESSENCE part 1 results for semaglutide 2.4 mg in MASH